A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 138
- Locations
- 4
- Primary Endpoint
- Percentage of Participants With Incidence of Grade II-IV GVHD
Study Overview
Brief Summary
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not yet approved bortezomib to treat or prevent graft-versus-host disease. Bortezomib is approved by the FDA to treat other human malignancies.
Bortezomib is a drug that has an anti-cancer effect that involves inhibiting cell growth and causing cell death. This drug has been used in other research studies, and information from thos other research studies suggests that bortezomib may help to lower the risk of GVHD after allogeneic stem cell transplantation in patients who have matched unrelated, unmatched related or unrelated donors in this research study.
Allogeneic stem cell transplantation is a procedure in which selected blood cells taken from your sibling or unrelated donor are given to you. Lower doses of chemotherapy drugs are given before the donor cells are infused in a process known as reduced-intensity conditioning. Stem cell transplant destroys cancer in two ways: The conditioning regimen destroys cancer cells and teh immune cells from the donor can recognize cancer cells and kill them.
A common problem after stem cell transplant is graft-versus-host disease (GVHD). The word "graft" refers to the donor blood cells that you will receive during your transplant. The word "host" refers to the person (in this case, you) receiving the cells. GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. GVHD can cause skin rash, intestinal problems such as nausea, vomiting or diarrhea. GVHD may also damage your liver and cause hepatitis or jaundice. GVHD may also increase your risk of infection.
After stem cell transplant, all patients receive prophylactic medications against GVHD. In this research study we are studying the safety and effectiveness of preventing GVHD using bortezomib treatment in combination with other drugs versus standard of care prophylaxis (tacrolimus + methotrexate). If you take part in this study, there is a 33% chance you will receive any one of the following GVHD prevention treatments:
- tacrolimus + methotrexate (standard of care GVHD prophylaxis)
- bortezomib + tacrolimus + methotrexate
- bortezomib + sirolimus + tacrolimus Sirolimus, tacrolimus and methotrexate are drugs that suppress the immune system to try to prevent GVHD.
Detailed Description
You will undergo some screening tests or procedures to find out if you can be in this research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. Possible tests include a medical history, physical exam, laboratory tests, pulmonary function tests, cardiac ejection fraction and a pregnancy test. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in the research study.
Because no one knows which of the study options is best, you will be "randomized" into one of the study groups (described below). Randomization means that you are put into a group by chance. It is like flipping a coin. You will have an equal chance of being placed in any of the groups.
Before your transplant you will receiving conditioning therapy. The conditioning therapy for this study involves fludarabine and busulfex. These drugs will be given five, four, three and two days before your transplant (Days -5 through -2). Both these chemotherapy drugs are commonly used in allogeneic stem cell transplantation. On Day 0, you will receive selected blood cells taken from your sibling or unrelated donor.
You will receive 1 of 3 GVHD prophylaxis plans depending on which one you are randomized to:
- Arm A will receive tacrolimus + methotrexate
- Arm B will receive bortezomib + tacrolimus + methotrexate
- Arm C will receive bortezomib + sirolimus + tacrolimus
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed advanced/aggressive hematologic malignancy unlikely to be cured by alternative therapies
- •HLA matched unrelated donors or 1-locus HLA mismatched related or unrelated donors
- •Adequate organ function
- •Willing to use appropriate contraception
Exclusion Criteria
- •Pregnant or breastfeeding
- •Recipient of prior allogeneic hematopoietic stem cell transplantation
- •Recipient of prior abdominal radiation therapy
- •HIV positive on combination anti-retroviral therapy
- •Seropositive for hepatitis B or C
- •Known allergy to bortezomib, boron or mannitol
- •Myocardial infarction within 6 months prior to enrollment or any other cardiac dysfunction
- •Uncontrolled infection
- •Inability to withhold agents that may interact with hepatic cytochrome P450 enzymes or gluthathione S-transferases
- •Seizures or history of seizures
- •Grade greater than or equal to 2 peripheral neuropathy within 21 days of enrollment
- •Use of other investigational drugs within 21 days of enrollment
- •History of another non-hematologic malignancy except if disease free for at least 5 years or cervical cancer in situ, or basal/squamous cell carcinoma of the skin
- •Uncontrolled intercurrent illness
Arms & Interventions
Arm A (Standard of Care)
Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
Intervention: Tacrolimus (Drug)
Arm A (Standard of Care)
Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
Intervention: Methotrexate (Drug)
Arm B (Experimental)
Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
Intervention: Tacrolimus (Drug)
Arm B (Experimental)
Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
Intervention: Methotrexate (Drug)
Arm B (Experimental)
Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
Intervention: Bortezomib (Drug)
Arm C (Experimental)
Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
Intervention: Tacrolimus (Drug)
Arm C (Experimental)
Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
Intervention: Bortezomib (Drug)
Arm C (Experimental)
Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
Intervention: Sirolimus (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With Incidence of Grade II-IV GVHD
Time Frame: 6 months
The primary outcome of this study is the cumulative incidence of grade II-IV acute GVHD up to Day 180 after stem cell infusion. Acute GHVD is graded according to the modified Glucksberg criteria (adapted from Thomas et al., NEJM ,1975, pp. 895-90), which is based on criteria by which the provider classifies acute GVHD per its objective organ staging. Acute GVHD is assessed in weekly standard of care visits post stem cell infusion and is captured in the protocol EDC upon evaluation of clinical notes up to Day 100. Data for acute GVHD organ staging and etiologies are collected in an acute GVHD separate case report form and do not include system organ class, expectedness or attribution.
Secondary Outcomes
- Percentage of Participants With Non-relapse Mortality(1 year)
- Percentage of Participants With Relapse(1 year)
- Percentage of Participants With Progression-free and Overall Survival(1 year)
- Percentage of Participants With Chronic Graft Versus Host Disease(1 year)
Investigators
John Koreth, MD
Principal Investigator
Dana-Farber Cancer Institute